RUNX1 mutations were analyzed in younger (<60 years of age; n = 175) and older (≥60 years of age; n = 225) patients with primary normal karyotype AML receiving intensive antileukemic therapy [67]. Here, RUNX1 is linked to acute myeloid leukemia.